Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Diabetes Obesity and Metabolism2022Vol. 24(7), pp. 1360–1369
Citations Over TimeTop 10% of 2022 papers
Victoria Parker, Thuong Hoang, Heike Schlichthaar, Fraser W. Gibb, Barbara Wenzel, Maximillian G. Posch, Ludger Rose, Yi‐Ting Chang, Marcella Petrone, Lars Hansen, Phil Ambery, Lutz Jermutus, Hiddo J.L. Heerspink, Rory J. McCrimmon
Abstract
We established the efficacy of cotadutide in this patient population, with significantly improved postprandial glucose control and reduced bodyweight versus placebo. Reductions in urinary albumin-to-creatinine ratios suggest potential benefits of cotadutide on kidney function, supporting further evaluation in larger, longer-term clinical trials.
Related Papers
- → Changes in Renal Function with Aging(1992)68 cited
- → Assessment of renal function by serum creatinine and creatinine clearance: glomerular filtration rate estimated by four procedures.(1989)41 cited
- The glomerular filtration rate: comparison of various predictive equations based on serum creatinine with conventional creatinine clearance test in Pakistani population.(2008)
- Laboratory evaluation of endogenous glomerular filtration rate in patients with various renal diseases(2009)
- → Spontaneous bleeding in a patient on enoxaparin with poor renal function(2019)